Development PipelineBrentuximab vedotin

an antibody–drug conjugate directed to CD30 being investigated in certain lymphomas and solid tumors

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

ECHELON-3: Diffuse large B-cell lymphoma

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

CheckMate 744: AYA CD30+ Hodgkin lymphoma

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGN35-015: Hodgkin lymphoma and CD30+ peripheral T-cell lymphoma

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGN35-027: Early and advanced stage Hodgkin lymphoma

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGN35-032: CD30-low and -negative peripheral T-cell lymphoma

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGN35-033: Metastatic non-small-cell lung cancer and melanoma

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

Program Resources

High-level synopsis of brentuximab vedotin and ongoing clinical trials

View/Download

Detailed information about brentuximab vedotin clinical trials

View in Interactive Pipeline